Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma.

摘要: Extensive efforts have been devoted to improve the diagnosis of extrahepatic cholangiocarcinoma (ECCA) due its silent clinical character and lack effective diagnostic biomarkers. Specific alterations in N-glycosylation glycoproteins are considered a key component cancer progression, which can serve as distinct molecular signature for detection. This study aims find potential serum N-glycan markers ECCA. In total, 255 samples from patients with ECCA (n = 106), benign bile tract disease (BBD, n = 60) healthy controls (HC, n = 89) were recruited. Only 2 μL individual was used this assay where N-glycome profiled by DNA sequencer-assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) technology. Multi-parameter models constructed combining N-glycans carbohydrate antigen 19-9 (CA19-9) is currently clinically. Quantitative analyses showed that among 13 structures, bifucosylated triantennary (peak10, NA3F2) presented best performance distinguishing BBD HC. Two (Glycotest1 Glycotest2) performed better than single or CA19-9. Additionally, two structures (peak9, NA3Fb; peak12, NA4Fb) tightly related lymph node metastasis patients. conclusion, sera relatively specific profiling patterns. Serum novel, valuable noninvasive alternatives progression monitoring.